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ABSTRACT 
 
Background and aim 
Cinacalcet effectively reduces calcium in patients with persistent hyperparathyroidism 
(HPT) after kidney transplantation. We aimed to assess the association of cinac
decrease in renal function based on a meta-analysis of observational studies in kidney 
transplant patients with persistent HPT. 
Method 
alcet with 
lysis of observational studies, no randomized controlled studies were available. 
he studies on kidney transplant patients with persistent HPT (8 studies, n=115), 
nal 
 
atment was associated with a decline of renal function in kidney transplant 
Meta-Ana
We calculated the mean difference between renal function before cinacalcet and at 3 
months on cinacalcet treatment for each study. Pooled analyses are based on random 
effects models. 
Results 
Pooling t
we found a significant reduction in renal function (p = 0.008). The effect size was 5 
μmol/l (p< 0.0001) when pooling the 7 studies where serum creatinine levels were 
reported. Meta-regression analysis revealed that there was an association between re
function and the amount of calcium reduction under treatment with cinacalcet. A higher 
delta change in serum calcium levels was associated with a decrease in renal function at 3
months of cinacalcet treatment.  
Conclusion 
Cinacalcet tre
recipients with persistent HPT. Our meta-analysis underscores the need for frequent 
monitoring of creatinine and calcium levels during cinacalcet treatment.  
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INTRODUCTION 
Cinacalcet is a calcimimetic drug that increases the sensitivity of the calcium-sensing 
receptor (CaSR) to extracellular calcium, which leads to a decrease of parathyroid 
hormone secretion and subsequently to lower serum calcium concentrations [1, 2]. The 
agent has been approved for treatment of dialysis patients with secondary 
hyperparathyroidism (HPT), and has substantially expanded the therapeutic options in the 
management of HPT.  
 
Persistent HPT with subsequent hypercalcemia after renal transplantation occurs 
frequently [3, 4] and is a risk factor for bone disease, promote vascular and 
tubulointerstitial calcifications and has been associated with decreased graft survival and 
enhanced post-transplant cardiovascular morbidity and mortality [5-8]. Effective control 
of persistent HPT is an important therapeutic goal after renal transplantation but poses a 
particular challenge. As active vitamin D treatment and calcium supplementation are 
contraindicated because they promote hypercalcemia, parathyroidectomy often remains 
the only therapeutic option. Encouraged by the success of cinacalcet to control 
biochemical parameters of HPT in dialysis patients [9], several studies including our own 
have shown that treatment with cinacalcet effectively corrects hypercalcemia in these 
patients [10-19]. Given the efficacy of cinacalcet to control hypercalcemia and the 
limited therapeutic options in these patients, cinacalcet has been off-label used in many 
transplant clinics. Hence, the awareness of a potential harmful effect of cinacalcet on 
renal function is of particular importance.  
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Yet recently, investigators reported conflicting results of the effect of cinacalcet on renal 
function as well as cases of acute kidney failure after the initiation of cinacalcet in 
patients with intractable primary hyperparathyroidism [20]. However, the effect of 
cinacalcet on renal function was not systematically investigated. First, since cinacalcet 
treatment was established mainly in dialysis patients, a renal-specific adverse effect of 
cinacalcet would not have been detectable. Notably, renal function was not reported in 
phase III studies of patients with primary HPT [21]. Second, the planed phase III studies 
in kidney transplant patients with hypercalcemia due to persistent HPT is designed to test 
cinacalcet profound effect on parathyroid hormone (PTH) and serum calcium and thus 
smaller effects on renal function will maybe not found.  
 
The primary goal of our analyses was to determine the short term effect of cinacalcet on 
renal function in renal transplant patients with persistent hyperparathyroidism by 
performing a systematic review of the literature and meta-analysis of peer-reviewed 
reports.  
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METHODS 
Search Strategy and Data Extraction 
We conducted a systematic search for relevant English and non-English publications 
using Medline (Ovid, Pubmed) for the period January 1990 to August 2009 and 
EMBASE for January 1990 to August 2009. We searched reference lists and abstracts 
presented at the American Society of Nephrology from 2002 to 2008. Search terms 
included “cinacalcet” or “mimpara” or “sensipar” or “calcimimetic*” or “R586”. 
Eligibility and exclusion criteria were pre-specified. No consensus procedure was 
necessary because identical data were extracted by the two reviewers (JH, ALS). 
Eligibility and exclusion criteria, as well as subgroup variables for potential sources of 
heterogeneity and their priority were pre-specified. 
 
Eligible Studies 
We included trials that studied oral cinacalcet in adult kidney transplant patients with the 
diagnosis of hyperparathyroidism (HPT) with a minimum follow up of at least 1 month. 
To be included in the primary analysis we required that renal function was assessed at 
baseline and at follow up (>1 months and ≤3 months). Eligible studies that did not meet 
the criteria for the primary analysis were included in a sensitivity analysis including 
studies with different follow-up times among study participants.  
 
Ineligible Studies 
We excluded case reports, reviews, letters, editorials, and non peer-reviewed 
publications. We also excluded animal investigations, phase I studies, studies in patients 
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on dialysis, studies on patients with primary or secondary HPT, studies on lithium 
induced HPT and studies on patients with hyperparathyreoid carcinoma.  
 
Definitions 
Our primary outcome measure was the mean difference of renal function between 
baseline and follow-up for each study assessed by pre-/post-treatment serum creatinine or 
estimated or measured GFR.  
 
Studies identified for Primary Analysis 
A total of 8 separate studies were identified in patients with persistent HPT after kidney 
transplantation (Table 1) [12, 14, 17, 18, 22-25]. 
 
Studies identified for Sensitivity Analysis 
In sensitivity analyses, we examined the effect of cinacalcet on renal function when 
including studies meeting less stringent quality criteria. 3 studies were identified for the 
sensitivity analysis on persistent HPT after kidney transplantation [10, 26, 27]. Two 
studies were excluded from the primary analysis for their high variability in follow-up 
time among patients (3-18 months) and one for not peer reviewed.  
 
Statistical Analysis 
The primary outcome of the pooled analysis was the mean difference in renal function 
before cinacalcet initiation and at follow-up of each study. As renal function was assessed 
by serum creatinine in micromole per liter or glomerular filtration rate (GFR) in milliliter 
per minute we calculated the pooled random-effects mean difference and 95% CI 
between pre-treatment and post-treatment values divided by the pooled standard 
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deviation (Hedges’s g). The correlation factor pre-/post-treatment serum creatinine was 
calculated from raw data (r=0.95, n=22) from 2 studies [14, 22] and was used as an 
estimate for the others. Results from all studies were then pooled using random effects 
models.  
 
Heterogeneity among studies was explored using the Q-statistic as a test (considered 
significant for p-values <0.10) and I2 that ranges between 0% and 100% with lower 
values representing less heterogeneity. Predefined subgroup analyses were performed for 
mean difference in serum calcium levels using visual inspection, and random-effect meta-
regression analysis. 
 
To assess potential publication bias, we used Begg’s and the Egger’s tests and Begg’s 
funnel plot; no evidence of bias was seen. Statistical analysis was performed by using 
comprehensive meta-analysis (CMA) version 2. 
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RESULTS 
A total of 1157 articles were found in our initial search, 1095 of which could be excluded 
by screening the titles and abstracts (Figure 1). A further 51 articles were excluded 
because they did not meet the inclusion criteria. 4 studies were excluded due to 
duplicates. Table 1 displays the characteristics of the 8 studies that met our inclusion 
criteria and of 3 studies that were included in the sensitivity analysis. All studies were 
performed to test the efficacy of cinacalcet on PTH and calcium reduction. 
 
Primary analyses of studies on persistent HPT after kidney transplantation 
8 studies involved a total of 115 patients (mean age 53.6 years) with stable allograft 
function (mean time after transplantation 37.8 months, range 6 to 74 months) [12, 14, 17, 
18, 22-25]. Mean follow up time was 5.7 months (range 1 to 12 months). Cinacalcet was 
given in a start-dose of 30 mg/d in 7 studies and 60 mg/d in 1 study. At end of follow-up 
mean dose was 47.25 mg/d (Table 1). 
 
Figure 2 shows the forest plot for the mean difference in renal function (as Hedges’s g) 
under treatment with cinacalcet in renal allograft patients with persistent HPT. Pooling 
the 8 studies there was a significant association between cinacalcet treatment and decline 
of renal function (mean difference of Hedges’s g -0.188 (95% CI, -0.327 to -0.048), 
p=0.008). Pooling 7 studies reporting serum creatinine levels, mean serum creatinine 
increased by 5 µmol/L (95% CI, 2.4 to 7.5, p<0.0001). There was no significant 
heterogeneity in results among studies (Q-test: p-value = 0.16, I2 33.6%) (Table 2). In 6 
out of the 8 studies from our primary analysis concomitant treatment was unchanged. 
When pooling these studies, the association between cinacalcet treatment and decline of 
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renal function remained significant (mean difference of Hedges’s g -0.180 (95% CI, -
0.310 to -0.051, p=0.006) and no significant heterogeneity in results among studies (Q-
test: p-value = 0.34, I2 11.3%) was detected. 
 
Subgroup-analysis 
Random effects meta-regression analysis revealed a significant association between 
change in serum calcium levels and decline in renal function (Figure 3, β = –2.05, 
p=0.004). For subgroup analysis studies were dichotomized into studies with higher and 
lower serum calcium change based on the median. In the low calcium change group [12, 
17, 23, 25], the pooled mean difference of Hedges’s g was -0.018 (95% CI, -0.186 to 
0.150) with lower calcium reduction compared to -0.315 (95% CI, -0.46 to -0.167, p 
value < 0.001) for trials with higher calcium reduction [14, 18, 22, 24]. Pooling 3 studies 
reporting serum creatinine and low delta calcium, serum creatinine remained unchanged 
(0.3 µmol/L, 95% CI; -9.0 to 9.6, p=0.95) and in the high delta calcium group, serum 
creatinine increased by 5.6 µmol/L (95% CI, 2.5 to 8.6, p<0.0001).  
 
Sensitivity analysis 
After adding 3 studies that did not meet our criteria for the primary analysis (Table 1) to 
the 8 trial of the primary analysis (total n = 162 individuals), the pooled mean difference 
of Hedges’s g was -0.100 (95% CI, -0.193 to -0.007, p-value 0.035). However, variation 
among the 11 trials was larger than expected (Q-test: p = 0.043, I2 47%) suggesting that 
the follow-up time point introduces heterogeneity. 
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DISCUSSION 
Based on small observational studies, we found an association between cinacalcet 
treatment and decline in renal function among renal allograft recipients with persistent 
HPT. The decline of renal function was related to the degree of calcium reduction during 
follow-up of 1 to 3 months.  
 
We found a small but significant (P=0.008) decline in renal function observed in our 
meta-analysis. In 5 out of 8 studies eligible for primary analysis, renal function tended to 
decline. After adding 3 studies (total n=162 patients) that did not meet our criteria for 
primary analysis, the pooled mean difference remained significant. Pooling 7 studies 
reporting serum creatinine levels, the mean serum creatinine increased by 5 µmol/L. The 
difference was highly significant (P<0.0001) although the absolute difference appears to 
be small. The serum creatinine high inter-subject variability may have diminished the 
true difference in our study and thus we can not exclude that our meta-analysis 
underestimated the effect. Indeed, we prospectively measured serum creatinine and 
estimated GFR values in 10 kidney allograft recipients with persistent 
hyperparathyroidism after cinacalcet treatment start, cinacalcet withdrawal and re-
exposure. Mean serum creatinine values increased by 12 µmol/l (95% CI 40 to -16) and 
11 µmol/l (95% CI 40 to -16) and estimated GFR (MDRD) decreased by 6 ml/min (95% 
CI -20 to 8) and 6 ml/min (95% CI -21 to 8) after cinacalcet initiation at week 0 and 
cinacalcet re-exposure at week 30, respectively (Figure 4).  
 
Our observation that cinacalcet initiation, withdrawal and re-exposure changed serum 
creatinine fast and reversible as well as the finding of two studies reporting a restoration 
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of renal function after cessation of cinacalcet [14, 19], suggests a hemodynamic rather 
than structural effects. The decline in renal function observed in our meta-analysis 
correlated very well with the delta serum calcium but not with delta PTH. This 
differential finding can be explained by unchanged pre-dose PTH levels but constantly 
reduced serum calcium levels over 24 hours in cinacalcet treated kidney transplant 
patients. Cinacalcet has the unique ability to suppress serum calcium persistently over 24 
hours, whereas PTH levels are only transiently reduced with a nadir 2-6 hrs after dosing 
[22]. Zoledronic acid is a bisphosphonate that lowers serum calcium levels to same 
magnitude compared to cinacalcet. In line with our meta-regression result, impairment of 
creatinine clearance was seen more often in subjects developing hypocalcemia than in 
those remaining normocalcemic [28] suggesting a common pathophysiologial 
mechanism.  
 
The results of our study have to be interpreted in the context of the available data and its 
quality, in particular, the limited information on changes of concomitant therapy and the 
absence of an untreated control. However, pooling 6 prospective studies reporting 
unchanged concomitant treatment, cinacalcet treatment was associated with a decrease of 
renal function. In total, only 8 studies met the inclusion criteria and they were small 
observational single centre studies in which renal function was not a predefined primary 
outcome measurement. It is debatable whether results of such observational studies 
should be pooled. However, drug safety call for formal meta-analysis as adverse effects 
are rare and unlikely to be found in studies designed for efficacy endpoint. It is also well 
accepted that the quality of a meta-analysis depends largely on the quality of the rough 
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data. The remarkable low heterogeneity in our study indicates robustness of the meta-
analysis and gives support to our hypothesis of a renal function decline in relation to the 
decrease of serum calcium which is in line with two previous reports of renal function 
restoration after cinacalcet withdrawal [14, 19]. Information on measured glomerular 
filtration rate was not available. However, change of renal allograft function within an 
interval of 3 months can reliably be assessed by serial measurements of serum creatinine 
levels in stable long-term kidney transplant patients.  
 
In summary, our results suggest that cinacalcet has a small but significant effect on renal 
function short-time after cinacalcet initiation in kidney transplant patients with persistent 
HPT. Our meta-analysis underscores the need for frequent monitoring of creatinine and 
calcium levels during cinacalcet treatment. 
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Table 1: Studies that assessed renal function before cinacalcet treatment and at follow-up 
Study, year Study design FU; month Study patients 
enrolled 
 (n male) 
Age (SD), years BL serum creatinine 
(SD) 
µmol/L 
BL  
GFR (SD) 
ml/min 
BL serum calcium, 
mmol/L 
BL and final 
cinacalcet dose,  
mg/day 
Kidney transplantation 
3° HPT, included in primary analysis 
El-Amm, 2007 [12] Cohort 
retrospective 
6 18 (8) 45 (13) 159 (97) 59 2.54 (0.22) 30 (60) 
Serra, 2007 [14] Cohort, 
prospective 
4 12 (6) 59 (2) 116 (30) 56 (16.6) 2.73 (0.14) 30 (34) 
Serra, 2008 [22] Cohort 
prospective 
1 10 (6) 59 (range 47-70) 134 (35) 49.7 (18.3) 2.55 (0.19) 30 (60) 
Bergua, 2008 [25] Cohort 
prospective 
12 9 (1) 61.8 (5.8) 140 (30) 51.4 (10.5) 2.92 (0.1) 30 (45) 
Borchhardt, 2008 [24] Cohort,  
prospective 
1.5 32 (22) 56 ( range 21-71)  138 (15) 48 (range 17-90) 2.77 (range 2.71-
2.80) 
30 (30) 
Szwarc, 2006 [17] Cohort 
prospective 
6 9 (9) 52 (11) NA 49.8 (18.6) 2.75 (0.15) 30 (55) 
Kruse, 2005 [18] Cohort 
retrospective 
3 14 (7) 23-65 (range)  
 
140 (56) NA 2.72 (0.11) 30 (30) 
Kamar, 2008 [23] Cohort,  
prospective 
12 11 (6) 50.5 (range 29-65) 119 (48) 56 (17) 2.68 (0.17) 60 (60) 
Kidney transplantation 
3° HPT, included in sensitivity analysis  
Srinivas, 2006 [16] Cohort, 
retrospective 
3-18 11 (6) 48.5 (range 22-64) 134 (42.1) NA 2.71 (0.1) 30 (NA) 
Apostolou, 2006 [10] Cohort, 
retrospective 
3- 18 7 (4) 56 (11) 140 (18) 
 
NA 1.89 (0.15) 30 (NA) 
Lopez, 2009 [27] Cohort 
prospective 
13 29 (14) 56 (11) NA 45 (16) 2.78 (0.2) 30 (60) 
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Table 2 
 
HPT type, study, year Change in renal function, 
mean (95% CI)  
p-value (Q-
test), I2 
Persistent HPT Estimated GFR (ml/min)  
Szwarc, 2006 [17] -0.9 (-9.9 to 8.1)  
   
Persistent HPT Serum creatinine (µmol/L)  
Kruse, 2005 [18] -8.0 (-13.2 to -2.8)  
El-Amm, 2007 [12] 0.0 (-26.9 to 26.9)  
Serra, 2007 [14] -12.0 (-24.1 to 0.1)  
Bergua, 2008 [25] 4.0 (-7.9 to 15.9)  
Borchhardt, 2008 [24] -3.0 (-6.3 to 0.3)  
Kamar, 2008 [23] -8.0 (-25.9 to 9.9)  
Serra, 2008 [22] -6.0 (-10.9 to -1.1)  
Pooled (random) -5 (-7.5 to – 2.4), p<0.0001 0.2, 34% 
   
Persistent HPT 
Subgroup analysis, 
Pooled (random) 
  
Mean difference serum 
calcium pre-/post-cinacalcet 
Serum creatinine (µmol/L)  
< 0.27 mmol/L [12, 23, 25] 0.3 (-9.0 to 9.6), p=0.95 0.6,0% 
≥0.27 mmol/L [14, 18, 22, 24] -5.6 (-8.6 to -2.5), p<0.0001 0.5, 0% 
Sensitivity analysis Hedges’s g  
All persistent HPT [10, 12, 
14, 16-18, 22-25] 
-0.100 (-0.193 to -0.007), p=0.035 0.055, 46% 
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Figure 1: QUOROM flow diagram  
(1157 articles found, of these 1052 could be excluded by heading) 
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Figure 2. Change of renal function during cinacalcet treatment in renal allograft 
recipients with persistent hyperparathyroidism.  
 
 
 
 
 
 
 
Legend Figure 2: Forest plot for Hedges’s g for change in serum creatinine or creatinine 
clearance during cinacalcet treatment. Size of squares is proportional to the number of 
study participants. Error bars represent the 95% confidence intervals. The confidence 
limits for the pooled change in renal function are indicated by the diamond-shaped figure. 
There was no significant heterogeneity (Q-test p-value: 0.16). Among renal allograft 
recipients with post-transplant persistent HPT, the pooled Hedges’s g was -0.188 (95% 
CI, -0.327 to -0048), p-value = 0.008).  
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Figure 3. Association between change in serum calcium levels and decline in renal 
function in patients with persistent hyperparathyroidism 3 months after initiation of 
cinacalcet treatment. 
 g ( ) g
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H
ed
ge
s'
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0.04
-0.04
-0.12
-0.20
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-0.36
-0.44
-0.52
-0.60
 
 
Legend Figure 3: Random effects meta-regression for change in serum creatinine or 
creatinine clearance (Hedges’s g) on delta serum calcium during cinacalcet treatment 
(β=–2.05, p=0.004). Size of circles is proportional to the number of study participants.  
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Figure 4. 
Mean serum creatinine values in 10 kidney allograft recipients with persistent 
hyperparathyroidism after cinacalcet treatment start, withdrawal and cinacalcet re-
exposure. 
 
 
 
 
Legend Figure 4: Mean serum creatinine values increased by 12 μmol/l (95% CI 40 to -
16) and 11 μmol/l (95% CI 40 to -16) and estimated GFR (MDRD) decreased by 6 
ml/min (95% CI -20 to 8) and 6 ml/min (95% CI -21 to 8) after cinacalcet initiation at 
week 0 and cinacalcet re-exposure at week 30, respectively.  
 
 
 
